You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Details for New Drug Application (NDA): 020222

✉ Email this page to a colleague

NDA 020222 describes COLESTID, which is a drug marketed by Pfizer and is included in two NDAs. It is available from two suppliers. Additional details are available on the COLESTID profile page.

The generic ingredient in COLESTID is colestipol hydrochloride. There are two drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the colestipol hydrochloride profile page.

Summary for 020222

Tradename:	COLESTID
Applicant:	Pfizer
Ingredient:	colestipol hydrochloride
Patents:	0

Pharmacology for NDA: 020222

Mechanism of Action	Bile-acid Binding Activity

Medical Subject Heading (MeSH) Categories for 020222

Anion Exchange Resins
Hypolipidemic Agents
Sequestering Agents

Suppliers and Packaging for NDA: 020222

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
COLESTID	colestipol hydrochloride	TABLET;ORAL	020222	NDA	Pharmacia & Upjohn Company LLC	0009-0450	0009-0450-03	120 TABLET in 1 BOTTLE (0009-0450-03)
COLESTID	colestipol hydrochloride	TABLET;ORAL	020222	NDA AUTHORIZED GENERIC	Mylan Pharmaceuticals Inc.	59762-0450	59762-0450-1	120 TABLET in 1 BOTTLE (59762-0450-1)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	1GM
Approval Date:	Jul 19, 1994	TE:	AB	RLD:	Yes

Expired US Patents for NDA 020222

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	COLESTID	colestipol hydrochloride	TABLET;ORAL	020222-001	Jul 19, 1994	⤷ Get Started Free	⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.